By Michael Dabaie

 

Hookipa Pharma Inc. said it is in a clinical collaboration and supply agreement with Merck & Co. to evaluate HB-200 and Keytruda for patients with advanced head and neck squamous cell carcinoma.

Shares of Hookipa rose 5.6% to $6.57 in premarket trading.

Hookipa said the collaboration was initiated based on promising data from the continuing HB-200 Phase 1/2 clinical trial in advanced human papillomavirus 16-positive cancers.

With an HB-200 program data read-out anticipated by the fourth quarter of 2021, Hookipa said it anticipates initiating a Phase 2 trial with HB-200 in combination with Keytruda in 2022. The company said it is planning additional Phase 2 expansion cohorts to start in the first quarter of 2022.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

September 15, 2021 08:02 ET (12:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Merck Charts.